| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| LianBio | Mavacamten | Precision Diastolic Disease (HFpEF) | Phase 2 | oral | Cardiology | |
| LianBio | NX-13 - (NEXUS) | Ulcerative Colitis (UC) | Phase 2 | Ongoing | Oral | Gastroenterology |
| LianBio | Omilancor (BT-11) | Crohn’s Disease | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| LianBio | Omilancor (BT-11) | Ulcerative Colitis | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| Ligand Pharmaceuticals Incorporated | Lasofoxifene + abemaciclib - (ELAINE-3) | ER+/HER2- breast cancer with an ESR1 mutation | Phase 3 | Enrollment Initiation | Oral | Oncology |
| Ligand Pharmaceuticals Incorporated | Lasofoxifene - (ELAINE 1) | ER+/HER2- breast cancer | Phase 3 | Oral | Oncology | |
| Ligand Pharmaceuticals Incorporated | CS1001 | Gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma. | Phase 3 | Intravenous | Oncology | |
| Ligand Pharmaceuticals Incorporated | V116 - (STRIDE-10) | Pneumococcal vaccine | Phase 3 | Data Released | Intramuscular | Immunology |